Medicina
Facultad
![Foto de Medicina](/img/uploaded/B3F8E74FDA254B3134B0031201D4E115.jpg)
![Foto de National Cancer Center Hospital](/img/noimage_org.png)
National Cancer Center Hospital
Kashiwa, JapónPublicaciones en colaboración con investigadores/as de National Cancer Center Hospital (82)
2024
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Annals of Oncology
-
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial
Lung Cancer, Vol. 189
-
Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists
Histopathology, Vol. 84, Núm. 3, pp. 429-439
-
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
The Lancet Oncology, Vol. 25, Núm. 5, pp. 572-587
-
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
European Journal of Cancer, Vol. 207
2023
-
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
JTO Clinical and Research Reports, Vol. 4, Núm. 1
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Annals of Oncology
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
-
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Cancers, Vol. 15, Núm. 16
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375
-
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Journal of Clinical Oncology
-
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185
-
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036
-
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075
-
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2893-2903
2022
-
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487
-
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192
-
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308